Citations

Clear

1906 citation(s) found for "Yu, Frank".

Enabling a learning healthcare system with automated computer protocols that produce replicable and personalized clinician actions
Morris, Alan H. , Orme, James F., Clemmer, Terry P., Weaver, Lindell K., Thomas, Frank, Grissom, Colin K. , Hirshberg, Ellie , East, Thomas D. , Wallace, C. Jane, Young, Michael , Sittig, Dean F. , Bombino, Michela, Beck, Eduardo, Sward, Katherine , Phansalkar, Shobha, Bernard, Gordon R. , Brower, Roy G., Truwit, Jonathon D. , Steingrub, Jay, Willson, Douglas F., Randolph, Adrienne G. , Curley, Martha A. Q. , Newth, Christopher J. L. , Lacroix, Jacques, Agus, Michael S. D. , Lee, Kang H., deBoisblanc, Bennett P., Evans, R. Scott, Sorenson, Dean, Wong, Anthony, Boland, Michael V. , Grainger, David W. , Dere, W. , Crandall, Alan S. , Huff, Stanley M. , Haug, Peter J. , Pielmeier, Ulrike , Rees, Stephen Edward , Karbing, Dan Stieper , Goldring, Roberta M. , Berger, Kenneth I. , Oppenheimer, Beno W. , Pickering, Brian W. , Schoenfeld, David , Tocino, Irena , Savitz, Lucy A., Dreyfuss, Didier, Slutsky, Arthur S. , Crapo, James D. , Pinsky, Michael R. , James, Brent C., Berwick, Donald M. , Sittig, Dean F , Weir, Charlene , Randolph, Adrienne G , Sward, Katherine A , Stagg, Brian C. , Lanspa, Michael J. , Pesenti, Antonio Maria , Thompson, Bruce , Hite, R. Duncan , Zimmerman, Jerry J. , Nadkarni, Vinay , Facelli, Julio Cesar , Andreassen, Steen , Fan, Eddy , Ely, Eugene Wesley , Gajic, Ognjen , Gonnering, Russell S , Pronovost, Peter J. , Angus, Derek C.

Mayo Clinic

Journal of the American Medical Informatics Association | November 11, 2020 | Volume: 28 | Issue: 6 | Pages: 1330-1344

10.1093/jamia/ocaa294 | PMID 33594410 Get It

AbstractClinical decision-making is based on knowledge, expertise, and authority, with clinicians approving almost every intervention—the starting point for delivery of “All the right care, but only the right care,” an unachieved healthcare quality improvement goal. Unaided clinicians suffer from human cognitive limitations and biases when decisions are based only on their training, expertise, and experience. Electronic health records (EHRs) could improve healthcare with robust decision-support tools that reduce unwarranted variation of clinician decisions and actions. Current EHRs, focused on results review, documentation, and accounting, are awkward, time-consuming, and contribute to clinician stress and burnout. Decision-support tools could reduce clinician burden and enable replicable clinician decisions and actions that personalize patient care. Most current clinical decision-support tools or aids lack detail and neither reduce burden nor enable replicable actions. Clinicians must provide subjective interpretation and missing logic, thus introducing personal biases and mindless, unwarranted, variation from evidence-based practice. Replicability occurs when different clinicians, with the same patient information and context, come to the same decision and action. We propose a feasible subset of therapeutic decision-support tools based on credible clinical outcome evidence: computer protocols leading to replicable clinician actions (eActions). eActions enable different clinicians to make consistent decisions and actions when faced with the same patient input data. eActions embrace good everyday decision-making informed by evidence, experience, EHR data, and individual patient status. eActions can reduce unwarranted variation, increase quality of clinical care and research, reduce EHR noise, and could enable a learning healthcare system.
428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)
Lewis, Karl D. , Peris, Ketty , Sekulić, Aleksandar , Stratigos, Alexander , Dunn, Lara , Eroglu, Zeynep , Chang, Anne Lynn S. , Migden, Michael R. , Li, Siyu , Mohan, Kosalai Kal, Coates, Ebony, Bechter, Oliver , Hernandez‐Aya, Leonel F. , Neves, Rogerio I. , Ruiz, E.P. Yanez, Seebach, Frank, Yancopoulos, George D., Lowy, Israel , Bowler, Timothy G., Fury, Matthew G., Okoye, Emmanuel, Baurain, Jean‐François , Hauschild, Axel , Butler, Marcus O. , Licitra, Lisa , Ruiz, Emily, Weinreich, David M.

Mayo Clinic

Regular and young investigator award abstracts | November 9, 2020 | Volume: No volume available | Issue: No issue available | Pages: A260.2-A261

10.1136/jitc-2020-sitc2020.0428 Get It

Pulmonary Root Mobilization and Modified Lecompte Maneuver for Transseptal Course of the Left Main Coronary Artery
Said, Sameh M. , Cetta, Frank

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | November 8, 2020 | Volume: 11 | Issue: 6 | Pages: 792-796

10.1177/2150135120939462 | PMID 33164682 Get It

Intraconal or transseptal course of the left main coronary artery is a rare form of coronary artery anomalies which has been linked to sudden death. We present details of the surgical technique that we used to address this challenging anomaly in two cases.
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
Usmani, Saad Z. , Stewart, A. Keith, Htut, Myo , O’Donnell, Elizabeth , Munshi, Nikhil C. , Avigan, David , Deol, Abhinav , Singh, Indrajeet , Zudaire, Enrique, Yeh, Tzu‐Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob , Goldberg, Jenna D., Schecter, Jordan M. , Jackson, Carolyn C. , Deraedt, William , Zhuang, Sen Hong, Infante, Jeffrey R., Geng, Dong , Wu, Xiaoling , Carrasco, Marlene J., Hossain, Farah , Rizvi, Syed , Fan, Frank, Martin, Thomas , Infante, Jon , Infante, Jon , Usmani, Saad , Madduri, Deepu , Berdeja, Jesús G. , Jakubowiak, Andrzej , Agha, Mounzer , Cohen, Adam D. , Hari, Parameswaran , Lesokhin, Alexander M. , Goldberg, Jenna D., Akram, Muhammad , Rizvi, Syed, Fan, Frank, Jagannath, Sundar , Lin, Yi

Mayo Clinic

Blood | November 4, 2020 | Volume: 136 | Issue: Supplement 1 | Pages: 22-25

10.1182/blood-2020-136307 Get It

Background: Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells) is a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity. In the phase 1 LEGEND-2 study in China, LCAR-B38M yielded deep, durable responses with a manageable safety profile in patients (pts) with relapsed/refractory multiple myeloma (R/R MM). The phase 1b/2 CARTITUDE-1 study (NCT03548207) is further evaluating cilta-cel in this pt population in the US. We present updated data from the phase 1b portion along with initial phase 2 data. Methods: Eligible pts (aged ≥18 y) were diagnosed with MM per International Myeloma Working Group (IMWG) criteria and had measurable disease, Eastern Cooperative Oncology Group performance status ≤1, received ≥3 prior regimens or were double-refractory to a proteasome inhibitor and immunomodulatory drug, and received an anti-CD38 antibody. After apheresis, bridging therapy was permitted. Cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 daily for 3 d were used for lymphodepletion. A single infusion of cilta-cel at a target dose of 0.75×106 (range 0.5-1.0×106) CAR+ viable T cells/kg was administered 5-7 d after start of lymphodepletion. The primary objective of the phase 1b portion was to characterize cilta-cel safety and establish the recommended phase 2 dose; the primary objective of the phase 2 portion was to evaluate cilta-cel efficacy. Response was assessed per IMWG criteria and minimal residual disease (MRD) by next-generation sequencing. Adverse events (AEs) were graded using CTCAE v5.0. In the phase 1b portion, cytokine release syndrome (CRS) was graded by Lee et al (Blood 2014) and neurotoxicity by CTCAE v5.0; in the phase 2 portion, CRS and neurotoxicity were graded by American Society for Transplantation and Cellular Therapy (ASTCT) criteria. In this combined analysis, Lee et al and CTCAE v5.0 were mapped to ASTCT criteria for CRS and immune effector cell-associated neurotoxicity syndrome (ICANS), respectively. Results: As of the May 20, 2020 clinical cutoff, 97 pts (58.8% male; median age 61.0 y [range 43-78]) with R/R MM received cilta-cel (29 in phase 1b; 68 in phase 2). Median follow-up duration was 8.8 mo (range 1.5-20.4). Pts had received a median of 6 prior lines of therapy (range 3-18); 83.5% were penta-exposed, 87.6% were triple-refractory, 41.2% were penta-refractory, and 97.9% were refractory to last line of therapy. Overall response rate per independent review committee (primary endpoint) was 94.8% (95% CI 88.4-98.3), with a stringent complete response rate of 55.7% (95% CI 45.2-65.8), very good partial response rate of 32.0% (95% CI 22.9-42.2), and partial response rate of 7.2% (95% CI 3.0-14.3). All pts achieved a reduction in M-protein. Median time to first response was 1.0 mo (range 0.9-5.8; 80.4% ≤1.0 mo), and median time to complete response or better was 1.8 mo (range 0.9-12.5; 74.1% ≤3.0 mo); responses deepened over time (Figure). Median duration of response was not reached (NR). Of 52 MRD-evaluable pts, 94.2% were MRD-negative at 10-5. The 6-mo progression-free survival (PFS) and overall survival (OS) rates (95% CI) were 87.4% (78.9-92.7) and 93.8% (86.7-97.2), respectively; median PFS and OS were NR. Ten deaths occurred during the study; 8 were due to AEs (both related and unrelated; CRS/hemophagocytic lymphohistiocytosis, neurotoxicity, respiratory failure, sepsis, septic shock, pneumonia, lung abscess, and acute myelogenous leukemia [n=1 each]), and 2 due to progressive disease. AEs reported in >70% of pts were CRS (94.8%; grade [gr] 3/4 4.1%), neutropenia (90.7%; gr 3/4 90.7%), anemia (81.4%; gr 3/4 68.0%), and thrombocytopenia (79.4%; gr 3/4 59.8%). Median time to CRS onset was 7.0 d (range 1-12) and median duration 4.0 d (range 1-27, excluding n=1 with 97 d). CAR-T cell-related neurotoxicity was reported in 20.6% of pts (gr 3/4 10.3%). Cilta-cel CAR+ T cells showed maximum peripheral expansion at 14 d (range 9-43). Among pts with 6 mo' individual follow-up, 67% had cilta-cel CAR+ T cells below the level of quantification (2 cells/µL) in peripheral blood. Conclusions: Preliminary phase 1b/2 data from CARTITUDE-1 indicate a single low-dose infusion of cilta-cel leads to early, deep, and durable responses in heavily pretreated pts with MM with a safety profile consistent with LEGEND-2. Further investigation of cilta-cel in other MM populations is underway. Disclosures Madduri: Celgene: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Foundation Medicine: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Legend: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; Kinevant: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau. Berdeja:Teva: Research Funding; Bluebird: Research Funding; Bioclinica: Consultancy; Celgene: Consultancy, Research Funding; EMD Sorono: Research Funding; Kite Pharma: Consultancy; Prothena: Consultancy; Cellularity: Research Funding; Karyopharm: Consultancy; Servier: Consultancy; Legend: Consultancy; Poseida: Research Funding; Lilly: Research Funding; Acetylon: Research Funding; CURIS: Research Funding; Janssen: Consultancy, Research Funding; Genentech, Inc.: Research Funding; Glenmark: Research Funding; Takeda: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Constellation: Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Vivolux: Research Funding; Abbvie: Research Funding; Amgen: Consultancy, Research Funding; Kesios: Research Funding; Novartis: Research Funding. Usmani:Celgene: Other; BMS, Celgene: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; GSK: Consultancy, Research Funding; Pharmacyclics: Research Funding; Merck: Consultancy, Research Funding; Abbvie: Consultancy; Sanofi: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Janssen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; SkylineDX: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Incyte: Research Funding; Array Biopharma: Research Funding; Amgen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding. Jakubowiak:Adaptive, Juno: Consultancy, Honoraria; AbbVie, Amgen, BMS/Celgene, GSK, Janssen, Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Cohen:Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda,: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Other: Patents/Intellectual property licensed, Research Funding. Stewart:Janssen, BMS, Sanofi-Aventis, GSK: Honoraria; Tempus, Inc., Genomics England LLC: Membership on an entity's Board of Directors or advisory committees. Hari:Amgen: Consultancy; BMS: Consultancy; GSK: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Incyte Corporation: Consultancy. Htut:City of Hope Medical Center: Current Employment. Munshi:OncoPep: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; BMS: Consultancy; Janssen: Consultancy; Adaptive: Consultancy; Legend: Consultancy; Amgen: Consultancy; Karyopharm: Consultancy; Takeda: Consultancy; AbbVie: Consultancy; C4: Current equity holder in private company. Deol:Novartis: Consultancy; Kite, a Gilead Company: Consultancy. Lesokhin:BMS: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; Janssen: Research Funding; Juno: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Serametrix Inc.: Patents & Royalties; GenMab: Consultancy, Honoraria. Singh:Janssen: Current Employment. Zudaire:Janssen: Current Employment. Yeh:Janssen: Current Employment. Allred:Janssen: Current Employment. Olyslager:Janssen: Current Employment. Banerjee:Janssen: Current Employment. Goldberg:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Schecter:Janssen: Current Employment. Jackson:Janssen: Current Employment; Memorial Sloan Kettering Cancer Center: Consultancy. Deraedt:Janssen: Current Employment, Current equity holder in publicly-traded company. Zhuang:Janssen: Current Employment. Infante:Janssen: Current Employment. Geng:Legend Biotech USA Inc.: Current Employment. Wu:Legend Biotech USA Inc.: Current Employment. Carrasco:Legend Biotech USA Inc.: Current Employment. Akram:Legend Biotech USA Inc.: Current Employment. Hossain:Legend Biotech USA Inc.: Current Employment. Rizvi:Legend Biotech USA Inc.: Current Employment. Fan:Legend Biotech USA Inc.: Current Employment. Jagannath:BMS, Janssen, Karyopharm, Legend Biotech, Sanofi, Takeda: Consultancy. Lin:Kite, a Gilead Company: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Merck: Research Funding; Legend BioTech: Consultancy; Juno: Consultancy; Bluebird Bio: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Vineti: Consultancy; Takeda: Research Funding; Gamida Cells: Consultancy; Sorrento: Consultancy, Membership on an entity's Board of Directors or advisory committees. Martin:AMGEN: Research Funding; Seattle Genetics: Research Funding; Janssen: Research Funding; GSK: Consultancy; Sanofi: Research Funding.
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Sha, Dan , Jin, Zhaohui , Budczies, Jan , Kluck, Klaus , Stenzinger, Albrecht , Sinicrope, Frank A. , Sinicrope, Frank A , Jin, Zhaohui

Mayo Clinic

Cancer Discovery | November 2, 2020 | Volume: 10 | Issue: 12 | Pages: 1808-1825

10.1158/2159-8290.cd-20-0522 | PMID 33139244 Get It

Abstract Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing–based estimates of TMB have largely replaced whole-exome sequencing–derived TMB in the clinic. Retrospective evidence suggests that TMB can predict the efficacy of immune checkpoint inhibitors, and data from KEYNOTE-158 led to the recent FDA approval of pembrolizumab for the TMB-high tumor subgroup. Unmet needs include prospective validation of TMB cutoffs in relationship to tumor type and patient outcomes. Furthermore, standardization and harmonization of TMB measurement across test platforms are important to the successful implementation of TMB in clinical practice. Significance: Evaluation of TMB as a predictive biomarker creates the need to harmonize panel-based TMB estimation and standardize its reporting. TMB can improve the predictive accuracy for immunotherapy outcomes, and has the potential to expand the candidate pool of patients for treatment with immune checkpoint inhibitors.
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine
Kopruszinski, Caroline Machado , Thornton, Peter , Arnold, Joanne, Lowne, David, Navratilova, Edita , Swiokla, Juliana, Dobson, Claire, Gurrell, Ian, Chessell, Iain P., Kopruszinski, Caroline , Navratilova, Edita , Newton, Philip, Dodick, David W. , Porreca, Frank

Mayo Clinic

Cephalalgia | November 2, 2020 | Volume: 40 | Issue: 14 | Pages: 1535-1550

10.1177/0333102420966581 | PMID 33131305 Get It

Aim Migraine pain is thought to result from activation of meningeal nociceptors that might involve dural mast cell degranulation and release of proteases and pronociceptive mediators. Tryptase, the most abundant dural mast cell protease, has been demonstrated to stimulate dural mast cells, as well as trigeminal nociceptors by activating the protease activated receptor 2. Mast cell or neuronal protease activated receptors 2 may therefore represent a novel target for migraine treatment. In this study, we characterized and evaluated a novel protease activated receptor 2 monoclonal antibody as a preventive anti-migraine pain therapy in preclinical models. Methods Flow cytometry, immunocytochemistry, calcium imaging, Homogeneous Time Resolved Technology (HTRF) epitope competition assay and serum pharmacokinetic (PK) assay in rats were performed to confirm the activity, specificity and in vivo stability of PAR650097, a novel anti- protease activated receptor 2 monoclonal antibody. In vivo assessment was performed in female C57BL/6J mice by evaluation of PAR650097 in preventing cutaneous allodynia elicited by (a) supradural injection of the protease activated receptor 2 agonist, Ser-Leu-Ile-Gly-Arg-Leu-amide trifluoroacetate (SLIGRL), or calcitonin gene-related (CGRP) peptide, and (b) induction of latent sensitization by priming with three daily episodes of restraint stress followed by challenge with a subthreshold inhalational exposure to umbellulone (UMB), a transient receptor potential ankyrin 1 (TRPA1) agonist. PAR650097 was administered as a pretreatment prior to the first restraint stress, umbellulone exposure, SLIGRL or calcitonin gene-related peptide injection. Additionally, fremanezumab, a calcitonin gene-related peptide antibody was administered as pre-treatment prior to supradural administration of calcitonin gene-related peptide or SLIGRL. Results In vitro, PAR650097 demonstrated rapid interaction with protease activated receptor 2, enabling it to fully inhibit protease-induced protease activated receptor 2 activation, in human and mouse cells, with high potency. Furthermore, PAR650097 was highly selective for protease activated receptor 2, demonstrating no affinity for protease activated receptor 1 protein and no functional effect on the activation of cellular protease activated receptor 1 with thrombin. In addition, PAR650097 had an acceptable PK profile, compatible with testing the effects of selective protease activated receptor 2 inhibition in vivo. In vivo, PAR650097 blocked cutaneous allodynia induced by either supradural SLIGRL or calcitonin gene-related peptide. Fremanezumab abolished cutaneous allodynia induced by supradural CGRP, and partially attenuated cutaneous allodynia induced by SLIGRL. Administration of PAR650097, before the first restraint stress episode, did not prevent the acute stress-induced cutaneous allodynia or restraint stress priming revealed by cutaneous allodynia induced by inhalational umbellulone. In contrast, PAR650097 prevented expression of cutaneous allodynia when given before the umbellulone challenge in restraint stress-primed animals. Conclusion PAR650097 specifically inhibits endogenously expressed protease activated receptor 2 in human and mouse cells with high potency. This antibody has an acceptable PK profile in rodents and effectively blocked SLIGR-induced cutaneous allodynia. PAR650097 additionally prevented cutaneous allodynia induced by supradural calcitonin gene-related peptide, indicating that the protease activated receptor 2 receptor is a downstream consequence of calcitonin gene-related peptide actions. Fremanezumab effectively blocked calcitonin gene-related peptide-induced cutaneous allodynia and only partially reduced cutaneous allodynia induced by a protease activated receptor 2 activator, suggesting both calcitonin gene-related peptide-dependent and -independent mechanisms in promoting migraine pain. While PAR650097 did not prevent stress-induced cutaneous allodynia or priming, it effectively prevented cutaneous allodynia induced by a TRPA1 agonist in animals with latent sensitization. Activation of protease activated receptor 2, therefore, contributes to both calcitonin gene-related peptide-dependent and -independent mechanisms in promoting migraine-like pain. Therapeutic targeting of protease activated receptor 2 receptors may represent an anti-migraine pain strategy with a potentially broad efficacy profile.
S1598 Insulinoma: A Recurrent Pancreatic Mass Amendable to CT-Guided Ethanol-Lipiodol Injection
Ghoz, Hassan , Alnahha, Khaled, Paz‐Fumagalli, Ricardo , Lukens, Frank , Zaver, Himesh B. , Raimondo, Massimo

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S814-S815

10.14309/01.ajg.0000708440.47860.c3 Get It

S3289 Obesity Is Associated With Worse Inpatient Outcomes and Greater Odds of Diverticular Bleed
Kröner, H, Palacios, Pedro , Riley, Guillermo, Campbell, Brian , Jimenez, Xavier , Lukens, Frank , Mönkemüller, Klaus , Kröner, Hans J., Kröner, Paul T. , Corral, Juan E. , Campbell, Brian, Jimenez, Xavier

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S1715-S1715

10.14309/01.ajg.0000715204.82642.3b Get It

S3238 Outcomes of Therapeutic Endoscopic Retrograde Cholangiopancreatography in a Community Hospital Setting
Oman, Sven P. , Kandel, Pujan , Graham, Lauren , Lukens, Frank , Ciofoaia, Victor, Khader, Mohammad, Graham, Lauren, Corral, Juan E.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S1694-S1694

10.14309/01.ajg.0000715000.76154.65 Get It

S1374 The Importance of Carnett's Sign in Patients With Gastroparetic Symptoms
McCallum, Richard W. , Wilson, Laura , Koch, Kenneth L. , Abell, Thomas, Shulman, Robert J. , Grover, Madhusudan , Farrugia, Gianrico , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , Sarosiek, Irene , Parkman, Henry P. , Kuo, Braden

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S692-S693

10.14309/01.ajg.0000707544.04241.a1 Get It